Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.97 USD | +6.93% |
|
+9.01% | +15.62% |
Jun. 25 | Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target | MT |
Jun. 18 | Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.62% | 1.66B | |
+20.95% | 127B | |
+23.00% | 117B | |
+25.15% | 27.77B | |
-19.75% | 20.44B | |
-16.57% | 16.62B | |
-16.56% | 15.92B | |
+11.19% | 14.74B | |
-46.65% | 14.94B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- KROS Stock
- News Keros Therapeutics, Inc.
- BTIG Adjusts Price Target on Keros Therapeutics to $105 From $95, Maintains Buy Rating